Search:
SHARE PRINT

Investing in immunisation through GAVI:
The evidence base


In a new report presented to partners, donors and potential donors, GAVI lays out the “Evidence Base’ for investing in its five year mission. Additional US$2.6 billion required to prevent 4.2 million future deaths


The Hague, the Netherlands, 24-25 March 2010 – In its first 10 years, GAVI has achieved remarkable results. By committing US$4 billion in funding to the world's poorest countries, our public-private global health partnership has accelerated 250 million children's access to new and underused vaccines and averted 5.4 million premature deaths.

Investing in immunisation through the GAVI Alliance: The evidence base
Download as PDF (3MB)
English | Français

In a new publication, presented to partners, donors and potential donors at a High-Level Meeting on Financing Country Demand in the Netherlands, GAVI presents the case for investing in its 2010-2015 mission: to double the number of lives saved in the Alliance's first decade.

If fully-funded, GAVI programmes will prevent an estimated 4.2 million future deaths by:

  • immunising more than 110 million children in 47 countries with pneumococcal vaccine
  • immunising 58 million children in 41 countries with the rotavirus vaccine
  • introducing new vaccines against yellow fever, meningitis A, Japanese encephalitis, human papillomavirus (HPV), rubella and typhoid, averting a further 150,000 future deaths

Additional US$2.6 billion needed

To achieve this goal, GAVI requires US$4.3 billion in donor funding over the next five years. The Alliance is confident that existing donor support will provide US$ 1.7 billion of its five-year funding requirement -- enough to cover current programmes and their extensions.

However, an additional US$2.6 billion is needed to roll-out pneumococcal and rotavirus diarrhoea vaccines as well as advance new vaccines like HPV.

Morally imperative, cost-effective

Drawing on published data and analyses, "The Evidence Base" states that investing in life-saving vaccines is both morally imperative and cost-effective. With immunisation coverage rates around 80 percent in many of the world's poorest countries, GAVI argues that no other public health programme has the capacity to reach more children.

The publication also documents GAVI's remarkable results over the past 10 years, reducing the delay that has historically characterised new vaccine introduction in low-income countries. It is no coincidence that GAVI support for Hepatitis B vaccine coincides with the rapid uptake of the vaccine in the world's poorest countries.

The final chapters describe the innovative approaches to development financing and programming that have become core to the GAVI business model and that have the potential to save an estimated 4.2 million lives in the next five years.

Click here to download the full publication as a PDF (3MB) >>